Description
USA DOMESTIC
Estimated delivery 1-2 weeks
What is Orforglipron?
Orforglipron is a new treatment for weight management. Orforglipron is a GLP-1 receptor agonist. This means it works in the same way as Wegovy and Mounjaro. Unlike those treatments, which are given as weekly injections, Orforglipron is taken as a daily pill.
These types of medicines were first developed to treat type 2 diabetes. Clinical trials then revealed that they also help people lose weight.
Orforglipron belongs to a new class of small-molecule, non-peptide medicines. Because of this, your body can break it down and absorb it properly when you take it by mouth.
Previous versions of oral GLP-1 treatments were too complicated for this method. Orforglipron is easier to use and offers better absorption, making it a simpler and more effective option.
How Does Orforglipron Work?
Orforglipron is a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by binding to your body’s GLP-1 receptors. These receptors are normally used to control your hunger.
When they are activated, they make you feel full. They also slow digestion to allow more to be drawn from the food you eat.
While this was originally designed to help people with type-2 diabetes, they had obvious applications for weight loss. In combination with a healthy diet and exercise, Orforglipron can make it easier for you to lose weight.
Orforglipron has a non-peptide structure. This allows it to be taken by mouth without losing effectiveness
Research has shown that Orforglipron keeps a high level of affinity even at lower receptor occupancy. This helps to minimize the risk of adverse outcomes while still providing an effective treatment outcome.
Clinical trials have already shown that at its highest dose, orforglipron can result in an average 11.2% weight loss compared to 2.1% with a placebo after 72 weeks, making it a promising alternative to weight loss injections.
How to Take Orforglipron?
As an oral pill, we expect Orforglipron to be taken once a day with or without food.
If you are using Orforglipron for weight loss, it is important to add exercise and change your diet. You may find Orforglipron to be less effective than it could be without these changes.
Orforglipron dosages
The FDA approved dosage schedule in the US for orforglipron (Foundayo) by Eli Lilly is:
- 0.8mg (starting dose)
- 2.5mg
- 5.5mg
- 9mg
- 14.5mg
- 17.2mg (maximum dose)
How to Store Orforglipron
Orforglipron should be stored in its original packaging at room temperature. This should be between 20°C and 25°C (68°F to 77°F).
Keep away from direct sunlight, moisture, and heat. Store out of reach of children and pets.
No self-injection required
Unlike medications like Mounjaro, Wegovy, and Nevolat, orforglipron is available as a daily pill and does not need to be injected. For anyone who would prefer not to inject themselves or has a fear of needles, GLP-1 pills could be a quicker, easier, and more convenient treatment option.
No food or water restrictions
Because orforglipron is a small molecule compound, it can be taken at any time of day, with or without food. Unlike some other GLP-1 medications, such as the Wegovy pill, it has no food, drink or timing restrictions, making it a more flexible option for some people.
Promising blood sugar stabilisation
Orforglipron looks promising as an effective type 2 diabetes treatment for people whose blood sugar levels have not been managed with insulin and lifestyle changes. Phase 3 trials show that even 6mg of daily orforglipron lowers blood glucose levels by 1.3% over 72 weeks compared to 1.8% at 36mg.
Effective weight management results
Orforglipron is showing promise in clinical research that it can effectively suppress hunger, contributing to weight loss. After 72 weeks of treatment, orforglipron helped up to 50.1% of people lose at least 10% of their starting body weight.
Orforglipron vs semaglutide vs tirzepatide
Clinical trial data specifically comparing orforglipron with other popular GLP-1 receptor agonists, like semaglutide (Wegovy) and tirzepatide (Mounjaro), is limited. However, using the available clinical research, we have found the following:
| How it’s taken | Effectiveness (average loss on max dose) | ||
|---|---|---|---|
| Orforglipron/Foundayo (orforglipron) | Oral tablet | 11.2% after 72 weeks (further clinical trials still required) | |
| Wegovy (semaglutide) | Weekly injection | Up to 21% after 72 weeks | |
| Mounjaro (tirzepatide) | Weekly injection | 22.5% after 72 weeks | |
| Nevolat (liraglutide) | Daily injection | 8% after 56 weeks |
